New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
08:31 EDTCERSCerus signs purchase agreement for deployment of INTERCEPT Blood System
Cerus announced that it has signed a two-year purchase agreement with two regional Swiss Red Cross Blood Services for deployment of the INTERCEPT Blood System for plasma in Lausanne and Zurich. These two pilot centers supply an estimated 15,000 plasma units annually. The INTERCEPT platelet system is currently used by all 13 Swiss Red Cross blood centers. Switzerland produces approximately 35,000 platelet units and 50,000 plasma units for transfusion annually.
News For CERS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:10 EDTCERSCerus price target raised to $8 from $6 at Cantor
Subscribe for More Information
05:50 EDTCERSCerus to host conference call
Subscribe for More Information
05:15 EDTCERSCerus confirms FDA approves INTERCEPT platelet system
Subscribe for More Information
December 17, 2014
09:22 EDTCERSOn The Fly: Pre-market Movers
HIGHER: Auspex Pharmaceuticals (ASPX), up 83.1% after Phase 3 trial of SD-809 met primary efficacy endpoint... Volcano (VOLC), up 55.3% after Philips (PHG) announced it will acquire the company for $18.00 per share... Paramount Gold and Silver (PZG), up 35.9% after announcing a merger agreement with Coeur Mining... Cerus (CERS), up 17.8% after FDA approves Intercept Blood System... American Apparel (APP), up 15.5% after terminating Dov Charney for cause... TASER (TASR), up 6.1% after LAPD purchases 860 AXON body-worn video cameras... Idera Pharmaceuticals (IDRA), up 5.9% after being called a top 2015 small cap pick at Piper Jaffray... Kandi Technologies (KNDI), up 7.5% after selling 1,000 electric vehicles to Chengdu City... Stillwater Mining (SWC), up 2.7% after being upgraded to Buy from Neutral at Goldman. DOWN AFTER EARNINGS: FedEx (FDX), down 3.5%... Joy Global (JOY), down 1.7%. ALSO LOWER: POZEN (POZN), down 13.1% after receiving a second complete response letter from the FDA for Yosprala... Cliffs Natural (CLF), down 13.1% after price target cut to $1 from $10 at Credit Suisse... Coeur Mining (CDE), down 2.8% following merger agreement with Paramount Gold and Silver.
06:50 EDTCERSCerus to host conference call
Subscribe for More Information
December 16, 2014
18:19 EDTCERSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Dave & Buster's (PLAY), up 7.3%... Darden Restaurants (DRI), up 1.6%. ALSO HIGHER: Auspex Pharmaceuticals (ASPX), up 66.5% after Phase 3 trial of SD-809 met primary efficacy endpoint... Cerus (CERS), up 26.6% after FDA approves Intercept Blood System... American Apparel (APP), up 8.6% after terminating Dov Charney for cause. DOWN AFTER EARNINGS: Heico (HEI), down 1%. ALSO LOWER: Cliffs Natural (CLF), down 10% after price target cut to $1 from $10 at Credit Suisse... Linn Energy (LINE), down 3% after being downgraded to Neutral from Outperform at RW Baird.
17:33 EDTCERSCerus confirms FDA approval of INTERCEPT Blood System for plasma
Subscribe for More Information
16:45 EDTCERSCerus up 28.7% after FDA approves Intercept Blood System
Subscribe for More Information
16:44 EDTCERSCerus Intercept Blood System approved by FDA
The FDA approved the Intercept Blood System for plasma, the first pathogen reduction system for use by blood establishments in the preparation of plasma in order to reduce the risk of transfusion-transmitted infections, or TTI. The Intercept Blood System for plasma may be used to reduce pathogens in plasma derived from whole blood and plasma obtained by apheresis, a collection process that separates red blood cells from plasma and then returns the red cells to the donor. Examples of some of the pathogens that may be reduced using the Intercept Blood System include HIV, hepatitis B and C viruses and West Nile virus. The adverse events experienced by patients who received plasma prepared using the Intercept Blood System for plasma were comparable to those experienced by participants who received plasma that had not been treated with the pathogen reduction device. The Intercept Blood System for plasma is marketed by Cerus. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use